Baxter International, Inc.

727 articles with Baxter International, Inc.

• Baxter to Host Third Quarter 2018 Financial Results Conference Call for Investors

  9/20/2018

  Baxter International Inc. will host a conference call to discuss its third quarter 2018 financial results on Wednesday, October 31, 2018, at 7:30 a.m. Central Time.

• Polyganics Strengthens Global Distribution Network with Appointment of Synovis MCA as US-wide Distributor of NEUROCAP®

  9/10/2018

  Polyganics today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. to be the exclusive distributor of its nerve capping device, NEUROCAP®, in the US.

• Baxter Announces U.S. FDA Clearance of New Bone Graft Substitute, Actifuse Flow

  9/6/2018

  Ready-to-use synthetic bone graft substitute designed for ease of use and fast application

• Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia and New Zealand

  8/1/2018

  Delivers a state-of-the-art system with proven Dose IQ Safety Software to help elevate the standard of patient safety

• Baxter Reports Second-Quarter 2018 Results and Increases Earnings Outlook for Full-Year 2018

  7/26/2018

  Second-quarter revenue of $2.8 billion increased 9 percent on a reported basis and 4 percent on an operational basis

• Baxter Announces Health Canada Approval of Spectrum IQ Infusion System

  7/25/2018

  Designed with Exclusive New Features for Bi-Directional Electronic Medical Records Integration Including Auto-Programming and Auto-Documentation

• Health Canada approves Baxter's 3-in-1 blood purification set for use in continuous renal replacement therapy and sepsis management protocols

  7/10/2018

  New indication to help remove excessive levels of cytokines and endotoxins in patients needing blood purification makes oXiris the first 3-in-1 set available in Canada

• Baxter to Host Second Quarter 2018 Financial Results Conference Call for Investors

  7/3/2018

  Baxter International will host a conference call to discuss its second quarter 2018 financial results on Thursday, July 26, 2018, at 7:30 a.m. Central Time.

• 

  A Look at the Top 10 Medical Device Companies in 2018

  6/12/2018

  The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.

• Baxter Unveiled Updates to SHARESOURCE Remote Patient Management Platform for Home Dialysis Patients at ERA-EDTA 2018

  5/30/2018

  Baxter International Inc. announced the availability of two program updates for its SHARESOURCE remote patient management platform to support greater accessibility and efficiencies in remotely viewing patient data.

• Baxter Supported Nine New Abstract Presentations at the 55th ERA-EDTA Congress That Further Demonstrate Value of HDx Therapy Enabled by THERANOVA

  5/30/2018

  Baxter International Inc. announced new data reinforcing that expanded hemodialysis (HDx) enabled by the THERANOVA dialyzer.

• Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference

  5/21/2018

  Company Increases Financial Guidance for 2020 and Provides Outlook for 2023

• Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System

  5/14/2018

  Designed with Exclusive New Features for Bi-Directional Electronic Medical Records Integration Including Auto-Programming and Auto-Documentation

• Baxter and the International Society of Nephrology Announce a Collaboration to Address Growing Prevalence of Kidney Disease

  5/2/2018

  Baxter International Inc. announced a partnership to advance chronic kidney disease (CKD) awareness and help improve access to therapy, particularly in low- and middle-income countries (LMIC) – commonly referenced as emerging markets – where the disease prevalence is growing the fastest.

• Baxter Reports First-Quarter 2018 Results and Increases Financial Outlook for Full-Year 2018

  4/26/2018

  First-Quarter Revenue of $2.7 Billion Increased 8 Percent on a Reported Basis and 3 Percent on an Operational Basis

• Baxter to Host First Quarter 2018 Financial Results Conference Call for Investors

  4/4/2018

  Baxter International, Inc. will host a conference call to discuss its first quarter 2018 financial results on Thursday, April 26, 2018, at 7:30 a.m. Central Daylight Time.

• Baxter International Inc. to Host Webcast of Annual Meeting of Stockholders

  4/2/2018

  Baxter International, Inc. will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time.

• 

  The Big Tease: Takeda Considers Buying Shire

  3/28/2018

  Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.

• Baxter Completes Acquisition of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio

  3/19/2018

  RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin and PREVELEAK Surgical Sealant is used in vascular reconstruction.

• Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase Authorization

  2/20/2018

  Baxter International Inc. (NYSE:BAX) today announced a quarterly cash dividend and an expanded authorization for its share repurchase program.